866-997-4948(US-Canada Toll Free)

Global Human Insulin Market 2015-2019

Published By :

Technavio

Published Date : Aug 2015

Category :

Insulin

No. of Pages : 63 Pages

About diabetes
Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.

Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

Key vendors
Eli Lilly
Novo Nordisk
Sanofi

Other prominent vendors
Biocon
Biodel
Biogenomics
Boehringer Ingelheim
Bristol-Myers Squibb
Diamyd Medical
Diasome Pharmaceuticals
DiaVacs
Pfizer
Generex Biotechnology
Lexicon Pharmaceuticals
Macrogenics
Merck
Oramed Pharmaceuticals
Osiris Therapeutics
Thermalin Diabetes
Tolerion
Wockhardt
XOMA Corporation

Market driver
Increase in prevalence of diabetes
For a full, detailed list, view our report

Market challenge
Stringent regulatory environment
For a full, detailed list, view our report

Market trend
Increasing R&D for novel mechanisms
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Product profiles
PART 04: Market research methodology
Research methodology
Economic indicators
PART 05: Disease overview
Epidemiology
PART 06: Pipeline analysis
PART 07: Introduction
Key market highlights
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by type of insulin
Fast-acting insulin
Intermediate-acting insulin
Long-acting insulin
PART 10: Market segmentation by type of disease
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
Lilly
Novo Nordisk
Sanofi
PART 19: Appendix
List of abbreviation
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Diabetes prevalence rate in various countries (2000 and 2030)
Exhibit 03: Global human insulin market 2014-2019 ($ Billions)
Exhibit 04: Five forces analysis
Exhibit 05: Global human insulin market by type of disease 2014
Exhibit 07: Global human insulin market segmentation by geography 2014
Exhibit 08: Impact of drivers
Exhibit 09: Impact of drivers and challenges
Exhibit 10: Novo Nordisk: Company strategy
Exhibit 11: Modern insulins: Drug sales 2010-2014 ($ millions)
Exhibit 12: NovoRapid/NovoLog: Drug sales 2010-2014 ($ millions)
Exhibit 13: Levemir: Drug sales 2010-2014 ($ millions)
Exhibit 14: NovoMix: Drug sales 2010-2014 ($ millions)
Exhibit 15: Human insulins: Drug sales 2010-2014 ($ millions)
Exhibit 16: Sanofi: Company strategy
Exhibit 17: Lantus: Drug sales 2010-2014 ($ millions)
Exhibit 18: Apidra: Drug sales 2010-2014 ($ millions)
Exhibit 19: Insuman: Drug sales 2010-2014 ($ millions)
Exhibit 20: Lilly: Company strategy
Exhibit 21: Humalog: Drug sales 2010-2014 ($ millions)
Exhibit 22: Humulin: Drug sales 2010-2014 ($ millions)
Exhibit 23: Novo Nordisk: R&D expenditure 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *